Introduction: The therapeutic landscape of Cushing’s disease (CD) has undergone a paradigm shift over the past decade. Medical therapy has evolved from nonspecific cortisol suppression toward precision-oriented molecular interventions that target adrenal steroidogenesis, pituitary receptor signaling, and tumor biology itself. For endocrine speciali